Daiichi Sankyo Company (4568) 44th Annual J.P. Morgan Healthcare Conference summary

Strategic overview and financial performance

• Transitioned from cardiovascular to oncology focus, doubling revenue and tripling profit over five years, driven by ENHERTU and DATROWAY.

• FY2025 revenue forecast at 2,100.0 Bn JPY, up 11.3% from FY2024, with 70% generated outside Japan, mainly the US.

• Core operating profit projected at 350.0 Bn JPY, a rise of 11.9%.

• Four consecutive years of dividend increases, targeting DOE of 8.5% in FY2025 and annual dividend of 78 JPY per share.

• New five-year business plan to be announced in April, focusing on sustainable growth and enhanced shareholder returns.

ADC technology and product pipeline

• DXd ADC platform recognized as industry-leading, with up to 14 Breakthrough Therapy designations in the US since 2017.

• ENHERTU established as standard of care in multiple HER2-positive cancer indications, achieving rapid market leadership and 1573.4 Bn JPY cumulative global net sales since launch.

• DATROWAY approved for HR-positive, HER2-negative breast cancer and EGFR-mutated lung cancer, with global net sales exceeding 10 Bn JPY in Q2 FY2025.

• New pivotal trials and indications for ENHERTU and DATROWAY expected to drive growth through 2030.

• Seven DXd ADCs developed, with several others in late-stage development targeting solid tumors and hematological malignancies.

Clinical and scientific innovation

• ENHERTU's first-line HER2-positive metastatic breast cancer indication shows significant survival benefits.

• DATROWAY's TROPION-Breast02 trial in triple-negative breast cancer demonstrated improved survival and response rates.

• Ongoing investment in immuno-oncology, combining IO agents with ADCs for complementary effects.

• Multimodality strategy includes ADCs, medium-sized molecules, nucleic acids, gene therapy, glycoengineering, and mRNA vaccines.

• Multiple World ADC Awards in 2025, including Best ADC Platform Technology.